Global Molecular Diagnostics Patent Landscape Report 2024

Global Molecular Diagnostics Market Size

The global molecular diagnostics market was valued at USD 20.573 billion in 2023. It is expected to grow at a CAGR of 8.2% during the forecast period of 2024-2032 and attain a market value of USD 40.922 billion by 2032.

The market growth is driven by the increasing prevalence of chronic and infectious diseases across the globe. Patents are focused on advanced technologies such as polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), chips and microarrays, mass spectrometry, sequencing, and transcription-mediated amplification among molecular diagnostics.

Patent Landscape Report Coverage

The Global Molecular Diagnostics Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for molecular diagnostics include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation associated with molecular diagnostics. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within molecular diagnostic technologies.

Key Inclusions

• Patent Valuation Analysis

An evaluation and competitive benchmarking of key members of unique patent families are covered in the analysis for molecular diagnostic technologies. The important parameters have been taken into consideration including IP document, year of application, number of citations, time to expiry, and jurisdiction associated with molecular diagnostics.

• Analysis of Patent Applications

A comprehensive summary of several patent applications which were filed across different jurisdictions for molecular diagnostics and their relative value are covered. The analysis will cover the capital in terms of innovation and innovation type.

• Analysis of Granted Patents

Detailed analysis of the granted patents across different jurisdictions for molecular diagnostics and their relative value in the IP are covered in the final report.

Molecular Diagnostics Patent Outlook

• Molecular diagnostic technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are gaining popularity owing to their accuracy and efficiency. These developments facilitate the creation of increasingly complex and user-friendly diagnostic instruments.

• The need for molecular diagnostics is increased by a rising preference for personalized medicine, which adjusts treatments based on each patient's unique genetic profile. These tests aid in the identification of specific biomarkers that direct individualized treatment regimens.

• The number of patent applications in the molecular diagnostic industry is on the rise, driven by growing patient and healthcare professional awareness of the advantages.

What are Molecular Diagnostics?

Molecular diagnostics involve a set of methods used to identify genetic disorders, diagnose diseases, and inform treatment choices by analyzing biological markers in the genome and proteome. These techniques frequently entail the identification of specific DNA, RNA, or protein sequences to deliver accurate, timely, and customized diagnostic data. Molecular diagnostics, using cutting-edge analytical technologies, are essential for managing and comprehending complicated conditions.

The components of molecular diagnostics include instruments, reagents and kits, along with services and software. Instruments are specialized tools used in tests for the identification and evaluation of proteins, genetic material, and other biomarkers. These tools, which include sequencers and PCR machines, offer comprehensive molecular insights that facilitate the accurate and timely identification of genetic disorders and diseases.

Molecular Diagnostics Industry Growth Drivers

Technological Advancement is Expected to Boost the Patent Industry Growth

Molecular diagnostics have benefitted from technological advancements that improve test speed, accuracy, and usability. Developments like next-generation sequencing (NGS) and sophisticated PCR methods propel market expansion by offering more accurate and comprehensive diagnostic data. For instance, Illumina introduced the NovaSeq X Series of sequencers, which provide much higher throughput at lower sample costs. The development of NGS technology allows for more thorough and economical genetic analysis, which contributes to the expansion of molecular diagnostics. Patents covering these technologies are crucial for companies and thus impacting the molecular diagnostics patent landscape.

As a result, there is an increase in patent activity which focuses on enhancing the performance of molecular diagnostics. There were 9,924 patents granted in 2022 which increased to 9,943 by 2023.

Growing Focus on Personalized Medicine is Expected to Propel Molecular Diagnostics Patent Industry 

There is an increasing need for molecular diagnostics due to a rising preference for personalized medicine, which bases treatment plans on individual genetic profiles. These tests aid in the identification of specific biomarkers, resulting in more specialized and efficient treatment plans.

Molecular Diagnostics Patent Segmentation

The report will cover the following sections in detail:

Analysis by Product & Service

• Instruments

• Reagents & Kits

• Services & Software

Analysis by Technology

• Polymerase Chain Reaction (PCR)

• In Situ Hybridization

• Isothermal Nucleic Acid Amplification Technology (INAAT)

• Chips and Microarrays

• Mass Spectrometry

• Sequencing

• Transcription Mediated Amplification

• Others

Molecular Diagnostics Patent Segmentation Analysis

The breakup based on technology includes polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), chips and microarrays, mass spectrometry, sequencing, transcription mediated amplification, and others. Isothermal nucleic acid amplification technology (INAAT) amplifies nucleic acids at a steady temperature without requiring intricate thermal cycling. This technology is especially helpful for field applications and point-of-care diagnostics because it makes genetic material detection quick, easy, and accurate.

Detailed technological data will be provided for all specified segments classified in this report.

Molecular Diagnostics Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for molecular diagnostics patents, having around 400,000+ patents. The presence of big companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the regional patent landscape significantly.

Patent Profile of Key Companies

Among the players with molecular diagnostics patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the molecular diagnostics field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Becton Dickinson Co.

A leading global provider of molecular diagnostic solutions and medical technology. It was established in 1897 and has its headquarters in Franklin Lakes, New Jersey. It is committed to enhancing patient outcomes by utilizing cutting-edge diagnostic tools and technologies. Solutions for managing cancer and identifying infectious diseases are part of the company's molecular diagnostics portfolio, which helps provide accurate and timely healthcare interventions.

Koninklijke Philips Electronics NV

A prominent player in the global health technology market, the company offers state-of-the-art solutions in molecular diagnostics. With its headquarters located in Amsterdam, Netherlands, Philips was founded in 1891. The company aims to develop advanced medical technology to enhance patient care and diagnostic precision. Through cutting-edge imaging and analytical tools, the company's molecular diagnostics innovations seek to improve disease detection and personalized medicine.

Other companies include Nanogen Inc, Wistron Corp, Almac Diagnostics Ltd, Genentech Inc, F. Hoffmann La Roche, Massachusetts Inst Technology, Bristol Myers Squibb Co, Amgen Inc, Dana Farber Cancer Inst Inc, Pioneer Hi Bred Int, Human Genome Sciences Inc, Pfizer Inc, Millennium Pharm Inc, among others.

Reasons to Purchase this Report

The molecular diagnostics patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and makes it understandable which companies have important patents in this field of molecular diagnostics.

• Innovation Insights: The patent analysis reveals new innovations and technologies in Molecular Diagnostics.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry within the molecular diagnostics patent landscape.

• Risk Assessment: In technology-intensive fields such as molecular diagnostics, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Molecular Diagnostics Patent Landscape Report 

• Who are the key players in the molecular diagnostics patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in molecular diagnostics patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the molecular diagnostics industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in molecular diagnostics?
• What are the challenges and opportunities in the molecular diagnostics patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in molecular diagnostics?

Related Reports

Molecular Diagnostics Market

Infectious Disease Molecular Diagnostics Market

Companion Diagnostics Market

Diagnostic Imaging Services Market